Previous Close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expire Date | 2024-12-20 |
Day's Range | 0.2000 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three-month period ended March 31, 2024.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides an innovative solution in non-opioid pain management. The U.S. Food and Drug Administration ("FDA") has granted Innocan an Investigational New Drug ("IND") number and approved an initial meeting with the Company to discuss the strategic path forward.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility.